Pfizer Inc. (PFE)
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer 2026: The Reset Year
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D spending of $10.5–$11.5 billion.
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.
Pfizer says patient dies after receiving hemophilia drug in trial
A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III studies and commercializing new assets, but near-term valuation upside is unlikely until clearer growth visibility emerges.
Pfizer Stock Can Sink More. Here Is How
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day.
